Information Transfer. In the event this Agreement is terminated, Xxxxx agrees to deliver to Seller within ten (10) days of Seller's written request copies of all materials received from Seller and any non-privileged plans, studies, reports, inspections, appraisals, surveys, drawings, permits, applications or other development work product relating to the Property in Buyer's possession or control as of the date this Agreement is terminated.
Information Transfer. There are policies, procedures and agreements concerning information transfer to/from third parties.
Information Transfer i) With respect to Jamf’s Hosted Services, Customer Content is encrypted in-transit to the Hosted Services and maintained in encrypted storage. Jamf will use industry standard encryption to encrypt Customer Content.
ii) Jamf will restrict access through encryption to Customer Content stored on media that is physically transported from Jamf facilities.
iii) Jamf will ensure that it is possible to verify and establish the extent to which Customer Content has been or may be transmitted or made available using data communication equipment.
Information Transfer. The Parties agree and acknowledge that Infinity has delivered to Novartis the information pursuant to Sections 2.2.4 and 3.3.3 of the Collaboration Agreement. From time to time during the term of this License Agreement, the Parties shall discuss any other information Controlled by Infinity that is necessary or useful for further development, manufacture and commercial exploitation and distribution of an Optioned Lead Program, Optioned Lead Program Compounds or Licensed Drug Product and Infinity shall promptly thereafter deliver such information to Novartis. This information shall also include copies of all Patents filed by Infinity pursuant to Section 2.3.2(h) of the Collaboration Agreement.
Information Transfer. TMRC shall, within [**] days after the Effective Date, provide Syros with all information that was made available to Syros in the Data Room and any other Licensed Know-how Rights possessed by TMRC or its Affiliates or in respect of which TMRC or its Affiliates otherwise have the right to grant licenses as of the Effective Date. Thereafter, on at least a [**] basis or more frequently as may be requested by Syros, TMRC shall provide Syros with updates to any chemistry, manufacturing and controls information relating to the Technology possessed by or otherwise available to TMRC or its Affiliates, if any, and with copies of or access to any other information within the Licensed Know-how Rights that Syros may request to satisfy requirements for Registrations or other required submissions to Competent Authorities, including source data and documents underlying any Registration and/or other regulatory documents to which Syros’s Right of Reference under Section 3.3 applies.
Information Transfer. In addition to the information required to be provided to the other Party in other provisions of this Agreement, each Party shall timely provide the other Party with (i) copies of all written correspondence with the Regulatory Authorities in the Territory regarding the Initial Product for use in the Territory, and (ii) a written summary of all oral communications with the Regulatory Authorities in the Territory regarding the Initial Product.
Information Transfer. Myogen shall deliver (to the extent not previously delivered to NIBRI pursuant to the Collaboration Agreement) as promptly as practicable to NIBRI all information in Myogen’s possession or under its control (including summaries of raw data from clinical studies conducted by Myogen of each Active Compound and related Myogen Target comprising the Development Candidate), all scientific reports, and all processes and procedures that are necessary or useful for further development, manufacture and commercial exploitation and distribution of the Development Candidate in the Territory. Such information shall include a summary of all material written communications (copies of which Myogen will provide to NIBRI at NIBRI’s request) between Myogen or (to the extent available to Myogen) its other licensees and the Food and Drug Administration (or any other similar regulatory authority) concerning the Development Candidate. This information shall also include copies of all Patents, copyrights, copyright registrations and applications therefor and all other manifestations of the intellectual property embodied in the Development Candidate, whether in human or machine readable form. Information provided by Myogen will be subject to the provisions of Article VI hereof.
Information Transfer. Seller agrees to make available to Purchaser upon request any and all information related to the installation, operation and maintenance of the facility and the use of the resource. Such data will be treated as confidential and can only be released by Purchaser with written permission of Seller, which permission shall not be unreasonably withheld. The parties will cooperate in developing mutually agreeable tests and/or modifications to be performed on the plant and resource.
Information Transfer. If Artiva elects to Manufacture Product itself; or to have Product Manufactured by a third party, Manufacturer will provide to Artiva, or its designee, all Manufacturing information, including, without limitation, Records, copy of the Master Batch Records, SOPs, documentation, technical assistance, materials and cooperation by appropriate employees of Manufacturer as Artiva or its designee may reasonably require in order to Manufacture Product. It is the intention of the parties that Artiva or its third party designee be able to replicate any Manufacturing Process developed by Manufacturer as part of the Services, and to Manufacture each Product in the same manner as Manufacturer Manufactured such Product pursuant to this Agreement, and the parties shall discuss and agree in good faith within [***] months of the Effective Date on a technology transfer plan for the parties to implement this Section 3.3.7. Artiva will compensate Manufacturer for such assistance at reasonable hourly rate(s) set forth in the applicable Work Order, or such other reasonable rate(s) as the parties may agree in writing. Agreement Confidential QA Controlled Document Master Agreement for Manufacturing Services Page 8 of 27 Effective Date/ DCR# Document/Version Number March 16, 2020 / DCR001 AGR001.01
Information Transfer. (i) As soon as practicable after the Effective Date, but in no case later than [**] days after the Effective Date, to the extent not previously disclosed to the other Party, each Party shall disclose to the other Party all non-clinical and clinical data (including all data from interim reviews, all source documents, and all case report forms and tabulations), internal and external reports, and all other Regulatory Documentation (the “Licensed Compound Information”) Controlled by such Party or its Affiliates (including, in MERRIMACK’s case, Merrimack Parent as successor to Hermes) and generated in the course of any Development activities conducted by such Party or its Affiliates (including, in MERRIMACK’s case, Merrimack Parent as successor to Hermes) pursuant to the 2005 License Agreement, and all Manufacturing Technology Controlled by such Party or its Affiliates (including, in MERRIMACK’s case, Merrimack Parent as successor to Hermes) and generated in the course of any manufacturing conducted by such Party or its Affiliates pursuant to the 2005 License Agreement. In addition, each Party shall disclose to the other Party Licensed Compound Information and Manufacturing Technology Controlled by such Party and generated in the course of Development and manufacturing activities conducted by such Party, as required by Section 4.4, Section 5.1, Section 6.1 and Section 6.2.
(ii) PEI hereby assigns and transfers to MERRIMACK a one-half, undivided ownership interest in and to all Licensed Compound Information and Manufacturing Technology, excluding Regulatory Documentation (which is addressed in Section 5.1), Controlled by PEI and generated by PEI prior to the Effective Date or following the Effective Date pursuant to this Agreement. Notwithstanding such co-ownership, MERRIMACK agrees that such Licensed Compound Information and Manufacturing Technology will be treated for all purposes under this Agreement as PEI Licensed Technology and MERRIMACK shall have the right to use, copy, practice, license and otherwise exploit such Licensed Compound Information and Manufacturing Technology solely (A) in connection with the Licensed Compound and the Licensed Product; and (B) to the same extent that MERRIMACK would be permitted to use, copy, practice, license and otherwise exploit such Licensed Compound Information and Manufacturing Technology under Section 8.2 if such Licensed Compound Information and Manufacturing Technology were not co-owned by MERRIMACK and were only pa...
